Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA449947
Max Phase: Preclinical
Molecular Formula: C34H28O22
Molecular Weight: 788.58
Molecule Type: Small molecule
Associated Items:
ID: ALA449947
Max Phase: Preclinical
Molecular Formula: C34H28O22
Molecular Weight: 788.58
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C(OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(O)c2)[C@H](OC(=O)c2cc(O)c(O)c(O)c2)[C@@H](OC(=O)c2cc(O)c(O)c(O)c2)[C@@H]1O)c1cc(O)c(O)c(O)c1
Standard InChI: InChI=1S/C34H28O22/c35-14-1-10(2-15(36)23(14)43)30(48)52-9-22-27(47)28(54-31(49)11-3-16(37)24(44)17(38)4-11)29(55-32(50)12-5-18(39)25(45)19(40)6-12)34(53-22)56-33(51)13-7-20(41)26(46)21(42)8-13/h1-8,22,27-29,34-47H,9H2/t22-,27-,28+,29-,34+/m1/s1
Standard InChI Key: RATQVALKDAUZBW-XPMKZLBQSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: Yes | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 788.58 | Molecular Weight (Monoisotopic): 788.1072 | AlogP: 0.70 | #Rotatable Bonds: 9 |
Polar Surface Area: 377.42 | Molecular Species: NEUTRAL | HBA: 22 | HBD: 13 |
#RO5 Violations: 3 | HBA (Lipinski): 22 | HBD (Lipinski): 13 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 7.55 | CX Basic pKa: | CX LogP: 3.41 | CX LogD: 3.11 |
Aromatic Rings: 4 | Heavy Atoms: 56 | QED Weighted: 0.06 | Np Likeness Score: 0.85 |
1. Kashiwada Y, Nonaka G, Nishioka I, Chang JJ, Lee KH.. (1992) Antitumor agents, 129. Tannins and related compounds as selective cytotoxic agents., 55 (8): [PMID:1431932] [10.1021/np50086a002] |
2. Lin T, Hsu F, Cheng J. (1993) Antihypertensive Activity of Corilagin and Chebulinic Acid, Tannins from Lumnitzera, racemosa, 56 (4): [10.1021/np50094a030] |
3. Nyamboki DK, Bedane KG, Hassan K, Brieger L, Strohmann C, Spiteller M, Matasyoh JC.. (2021) Cytotoxic Compounds from the Stem Bark of Two subsp. of Bersama abyssinica., 84 (5.0): [PMID:33974421] [10.1021/acs.jnatprod.0c01141] |
4. Kumar N, Kumar V, Anand P, Kumar V, Ranjan Dwivedi A, Kumar V.. (2022) Advancements in the development of multi-target directed ligands for the treatment of Alzheimer's disease., 61 [PMID:35398739] [10.1016/j.bmc.2022.116742] |
Source(1):